JP2020533296A - 薬物誘発性ジスキネジアを治療するためのプリドピジン - Google Patents
薬物誘発性ジスキネジアを治療するためのプリドピジン Download PDFInfo
- Publication number
- JP2020533296A JP2020533296A JP2020513603A JP2020513603A JP2020533296A JP 2020533296 A JP2020533296 A JP 2020533296A JP 2020513603 A JP2020513603 A JP 2020513603A JP 2020513603 A JP2020513603 A JP 2020513603A JP 2020533296 A JP2020533296 A JP 2020533296A
- Authority
- JP
- Japan
- Prior art keywords
- day
- predopidine
- administered
- levodopa
- dose
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000011282 treatment Methods 0.000 title claims description 109
- YGKUEOZJFIXDGI-UHFFFAOYSA-N pridopidine Chemical compound C1CN(CCC)CCC1C1=CC=CC(S(C)(=O)=O)=C1 YGKUEOZJFIXDGI-UHFFFAOYSA-N 0.000 title description 65
- 229950003764 pridopidine Drugs 0.000 title description 58
- 208000009985 drug-induced dyskinesia Diseases 0.000 title description 5
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 claims abstract description 254
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 claims abstract description 253
- 229960004502 levodopa Drugs 0.000 claims abstract description 251
- 208000012661 Dyskinesia Diseases 0.000 claims abstract description 193
- 238000000034 method Methods 0.000 claims abstract description 154
- 239000003814 drug Substances 0.000 claims abstract description 105
- 229940079593 drug Drugs 0.000 claims abstract description 103
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 76
- 208000016285 Movement disease Diseases 0.000 claims abstract description 67
- 208000018737 Parkinson disease Diseases 0.000 claims description 148
- 150000001875 compounds Chemical class 0.000 claims description 80
- 208000014094 Dystonic disease Diseases 0.000 claims description 58
- 208000010118 dystonia Diseases 0.000 claims description 58
- 208000024891 symptom Diseases 0.000 claims description 49
- 150000003839 salts Chemical class 0.000 claims description 37
- 206010008748 Chorea Diseases 0.000 claims description 34
- 208000012601 choreatic disease Diseases 0.000 claims description 34
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 30
- 206010034010 Parkinsonism Diseases 0.000 claims description 28
- 230000033001 locomotion Effects 0.000 claims description 22
- 206010044565 Tremor Diseases 0.000 claims description 12
- 208000002033 Myoclonus Diseases 0.000 claims description 11
- 206010043118 Tardive Dyskinesia Diseases 0.000 claims description 10
- 239000000935 antidepressant agent Substances 0.000 claims description 10
- 229940005513 antidepressants Drugs 0.000 claims description 10
- 239000003937 drug carrier Substances 0.000 claims description 10
- 206010003591 Ataxia Diseases 0.000 claims description 8
- 239000000164 antipsychotic agent Substances 0.000 claims description 8
- 229940005529 antipsychotics Drugs 0.000 claims description 8
- 239000003416 antiarrhythmic agent Substances 0.000 claims description 7
- 239000001961 anticonvulsive agent Substances 0.000 claims description 7
- 239000004083 gastrointestinal agent Substances 0.000 claims description 7
- 239000004050 mood stabilizer Substances 0.000 claims description 7
- 229940127237 mood stabilizer Drugs 0.000 claims description 7
- 239000003242 anti bacterial agent Substances 0.000 claims description 6
- 229940125695 gastrointestinal agent Drugs 0.000 claims description 4
- 230000001788 irregular Effects 0.000 claims description 4
- 230000002151 myoclonic effect Effects 0.000 claims description 4
- 208000027089 Parkinsonian disease Diseases 0.000 claims description 3
- 238000010586 diagram Methods 0.000 abstract 1
- 230000000694 effects Effects 0.000 description 82
- DKNWSYNQZKUICI-UHFFFAOYSA-N amantadine Chemical compound C1C(C2)CC3CC2CC1(N)C3 DKNWSYNQZKUICI-UHFFFAOYSA-N 0.000 description 52
- 229960003805 amantadine Drugs 0.000 description 51
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 44
- 239000000203 mixture Substances 0.000 description 40
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 35
- 101710104750 Sigma non-opioid intracellular receptor 1 Proteins 0.000 description 30
- 102100028656 Sigma non-opioid intracellular receptor 1 Human genes 0.000 description 30
- 241001465754 Metazoa Species 0.000 description 26
- 208000035475 disorder Diseases 0.000 description 26
- 208000023105 Huntington disease Diseases 0.000 description 24
- 229960003638 dopamine Drugs 0.000 description 22
- 230000027455 binding Effects 0.000 description 21
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 20
- 230000000648 anti-parkinson Effects 0.000 description 19
- 239000000939 antiparkinson agent Substances 0.000 description 19
- 239000003981 vehicle Substances 0.000 description 18
- 230000001186 cumulative effect Effects 0.000 description 16
- 238000011374 additional therapy Methods 0.000 description 15
- 238000009472 formulation Methods 0.000 description 15
- 102000005962 receptors Human genes 0.000 description 15
- 108020003175 receptors Proteins 0.000 description 15
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 14
- 229910052805 deuterium Inorganic materials 0.000 description 14
- 230000006872 improvement Effects 0.000 description 14
- 238000002560 therapeutic procedure Methods 0.000 description 14
- 238000011156 evaluation Methods 0.000 description 13
- 230000001225 therapeutic effect Effects 0.000 description 13
- 238000012360 testing method Methods 0.000 description 12
- 241000282553 Macaca Species 0.000 description 11
- 101001135571 Mus musculus Tyrosine-protein phosphatase non-receptor type 2 Proteins 0.000 description 11
- 238000004458 analytical method Methods 0.000 description 11
- 230000008859 change Effects 0.000 description 11
- PLRACCBDVIHHLZ-UHFFFAOYSA-N 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine Chemical compound C1N(C)CCC(C=2C=CC=CC=2)=C1 PLRACCBDVIHHLZ-UHFFFAOYSA-N 0.000 description 10
- UCTWMZQNUQWSLP-UHFFFAOYSA-N adrenaline Chemical compound CNCC(O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-UHFFFAOYSA-N 0.000 description 10
- -1 antipsychotic Substances 0.000 description 10
- 210000004369 blood Anatomy 0.000 description 10
- 239000008280 blood Substances 0.000 description 10
- 230000003993 interaction Effects 0.000 description 10
- 238000002600 positron emission tomography Methods 0.000 description 10
- 230000009467 reduction Effects 0.000 description 10
- 208000006083 Hypokinesia Diseases 0.000 description 9
- 201000010099 disease Diseases 0.000 description 9
- 238000001727 in vivo Methods 0.000 description 9
- 239000000902 placebo Substances 0.000 description 9
- 229940068196 placebo Drugs 0.000 description 9
- 206010006100 Bradykinesia Diseases 0.000 description 8
- 241000700159 Rattus Species 0.000 description 8
- 238000002648 combination therapy Methods 0.000 description 8
- 230000007423 decrease Effects 0.000 description 8
- 230000001976 improved effect Effects 0.000 description 8
- 230000036470 plasma concentration Effects 0.000 description 8
- 108050004812 Dopamine receptor Proteins 0.000 description 7
- 102000015554 Dopamine receptor Human genes 0.000 description 7
- 208000015592 Involuntary movements Diseases 0.000 description 7
- 238000000540 analysis of variance Methods 0.000 description 7
- 230000009286 beneficial effect Effects 0.000 description 7
- 210000004556 brain Anatomy 0.000 description 7
- 238000000338 in vitro Methods 0.000 description 7
- 230000017311 musculoskeletal movement, spinal reflex action Effects 0.000 description 7
- 230000004044 response Effects 0.000 description 7
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- 102000006441 Dopamine Plasma Membrane Transport Proteins Human genes 0.000 description 6
- 108010044266 Dopamine Plasma Membrane Transport Proteins Proteins 0.000 description 6
- ZGUGWUXLJSTTMA-UHFFFAOYSA-N Promazinum Chemical compound C1=CC=C2N(CCCN(C)C)C3=CC=CC=C3SC2=C1 ZGUGWUXLJSTTMA-UHFFFAOYSA-N 0.000 description 6
- KLBQZWRITKRQQV-UHFFFAOYSA-N Thioridazine Chemical compound C12=CC(SC)=CC=C2SC2=CC=CC=C2N1CCC1CCCCN1C KLBQZWRITKRQQV-UHFFFAOYSA-N 0.000 description 6
- 230000002051 biphasic effect Effects 0.000 description 6
- 210000003169 central nervous system Anatomy 0.000 description 6
- 238000009826 distribution Methods 0.000 description 6
- 230000003902 lesion Effects 0.000 description 6
- 238000011866 long-term treatment Methods 0.000 description 6
- 210000002381 plasma Anatomy 0.000 description 6
- 230000002829 reductive effect Effects 0.000 description 6
- 210000002966 serum Anatomy 0.000 description 6
- 238000001135 Friedman test Methods 0.000 description 5
- 241000282412 Homo Species 0.000 description 5
- 241000288906 Primates Species 0.000 description 5
- 230000000996 additive effect Effects 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- 238000011161 development Methods 0.000 description 5
- 230000018109 developmental process Effects 0.000 description 5
- 239000003136 dopamine receptor stimulating agent Substances 0.000 description 5
- 231100000673 dose–response relationship Toxicity 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 230000014509 gene expression Effects 0.000 description 5
- LNEPOXFFQSENCJ-UHFFFAOYSA-N haloperidol Chemical compound C1CC(O)(C=2C=CC(Cl)=CC=2)CCN1CCCC(=O)C1=CC=C(F)C=C1 LNEPOXFFQSENCJ-UHFFFAOYSA-N 0.000 description 5
- 230000001771 impaired effect Effects 0.000 description 5
- 230000000977 initiatory effect Effects 0.000 description 5
- YQZBAXDVDZTKEQ-UHFFFAOYSA-N loxapine succinate Chemical compound [H+].[H+].[O-]C(=O)CCC([O-])=O.C1CN(C)CCN1C1=NC2=CC=CC=C2OC2=CC=C(Cl)C=C12 YQZBAXDVDZTKEQ-UHFFFAOYSA-N 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 230000007246 mechanism Effects 0.000 description 5
- 230000007659 motor function Effects 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 229940076279 serotonin Drugs 0.000 description 5
- 101710138638 5-hydroxytryptamine receptor 1A Proteins 0.000 description 4
- 102100022738 5-hydroxytryptamine receptor 1A Human genes 0.000 description 4
- 101710138091 5-hydroxytryptamine receptor 2A Proteins 0.000 description 4
- 102100036321 5-hydroxytryptamine receptor 2A Human genes 0.000 description 4
- 102000004219 Brain-derived neurotrophic factor Human genes 0.000 description 4
- 108090000715 Brain-derived neurotrophic factor Proteins 0.000 description 4
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 4
- 108090001111 Dopamine D2 Receptors Proteins 0.000 description 4
- 102000004980 Dopamine D2 Receptors Human genes 0.000 description 4
- PLDUPXSUYLZYBN-UHFFFAOYSA-N Fluphenazine Chemical compound C1CN(CCO)CCN1CCCN1C2=CC(C(F)(F)F)=CC=C2SC2=CC=CC=C21 PLDUPXSUYLZYBN-UHFFFAOYSA-N 0.000 description 4
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 4
- 206010020751 Hypersensitivity Diseases 0.000 description 4
- PWWVAXIEGOYWEE-UHFFFAOYSA-N Isophenergan Chemical compound C1=CC=C2N(CC(C)N(C)C)C3=CC=CC=C3SC2=C1 PWWVAXIEGOYWEE-UHFFFAOYSA-N 0.000 description 4
- BATFHSIVMJJJAF-UHFFFAOYSA-N Morindone Chemical compound OC1=CC=C2C(=O)C3=C(O)C(C)=CC=C3C(=O)C2=C1O BATFHSIVMJJJAF-UHFFFAOYSA-N 0.000 description 4
- 102000008092 Norepinephrine Plasma Membrane Transport Proteins Human genes 0.000 description 4
- 108010049586 Norepinephrine Plasma Membrane Transport Proteins Proteins 0.000 description 4
- 239000000654 additive Substances 0.000 description 4
- 230000001800 adrenalinergic effect Effects 0.000 description 4
- 229940077737 brain-derived neurotrophic factor Drugs 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 208000001970 congenital sucrase-isomaltase deficiency Diseases 0.000 description 4
- 230000003247 decreasing effect Effects 0.000 description 4
- 230000003291 dopaminomimetic effect Effects 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- 239000003446 ligand Substances 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 210000002569 neuron Anatomy 0.000 description 4
- DIVDFFZHCJEHGG-UHFFFAOYSA-N oxidopamine Chemical compound NCCC1=CC(O)=C(O)C=C1O DIVDFFZHCJEHGG-UHFFFAOYSA-N 0.000 description 4
- 239000000700 radioactive tracer Substances 0.000 description 4
- 239000003381 stabilizer Substances 0.000 description 4
- 230000005062 synaptic transmission Effects 0.000 description 4
- 229960002784 thioridazine Drugs 0.000 description 4
- YGRHOYQMBLLGEV-UHFFFAOYSA-N 4-(3-methylsulfonylphenyl)-1-propylpiperidine;hydrochloride Chemical group Cl.C1CN(CCC)CCC1C1=CC=CC(S(C)(=O)=O)=C1 YGRHOYQMBLLGEV-UHFFFAOYSA-N 0.000 description 3
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 3
- 102100039126 5-hydroxytryptamine receptor 7 Human genes 0.000 description 3
- 101710150237 5-hydroxytryptamine receptor 7 Proteins 0.000 description 3
- 206010001541 Akinesia Diseases 0.000 description 3
- 108010072051 Glatiramer Acetate Proteins 0.000 description 3
- 241000282567 Macaca fascicularis Species 0.000 description 3
- KLPWJLBORRMFGK-UHFFFAOYSA-N Molindone Chemical compound O=C1C=2C(CC)=C(C)NC=2CCC1CN1CCOCC1 KLPWJLBORRMFGK-UHFFFAOYSA-N 0.000 description 3
- 208000007101 Muscle Cramp Diseases 0.000 description 3
- 238000012879 PET imaging Methods 0.000 description 3
- 241000283984 Rodentia Species 0.000 description 3
- 206010039897 Sedation Diseases 0.000 description 3
- 102000019208 Serotonin Plasma Membrane Transport Proteins Human genes 0.000 description 3
- 108010012996 Serotonin Plasma Membrane Transport Proteins Proteins 0.000 description 3
- GFBKORZTTCHDGY-UWVJOHFNSA-N Thiothixene Chemical compound C12=CC(S(=O)(=O)N(C)C)=CC=C2SC2=CC=CC=C2\C1=C\CCN1CCN(C)CC1 GFBKORZTTCHDGY-UWVJOHFNSA-N 0.000 description 3
- 208000024453 abnormal involuntary movement Diseases 0.000 description 3
- FHEAIOHRHQGZPC-KIWGSFCNSA-N acetic acid;(2s)-2-amino-3-(4-hydroxyphenyl)propanoic acid;(2s)-2-aminopentanedioic acid;(2s)-2-aminopropanoic acid;(2s)-2,6-diaminohexanoic acid Chemical compound CC(O)=O.C[C@H](N)C(O)=O.NCCCC[C@H](N)C(O)=O.OC(=O)[C@@H](N)CCC(O)=O.OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 FHEAIOHRHQGZPC-KIWGSFCNSA-N 0.000 description 3
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 3
- 229960004373 acetylcholine Drugs 0.000 description 3
- 101150109352 acr-16 gene Proteins 0.000 description 3
- 230000001154 acute effect Effects 0.000 description 3
- 230000002411 adverse Effects 0.000 description 3
- QWGDMFLQWFTERH-UHFFFAOYSA-N amoxapine Chemical compound C12=CC(Cl)=CC=C2OC2=CC=CC=C2N=C1N1CCNCC1 QWGDMFLQWFTERH-UHFFFAOYSA-N 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 230000001430 anti-depressive effect Effects 0.000 description 3
- 230000037007 arousal Effects 0.000 description 3
- 210000004227 basal ganglia Anatomy 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- 230000029142 excretion Effects 0.000 description 3
- 229940127227 gastrointestinal drug Drugs 0.000 description 3
- 229960003776 glatiramer acetate Drugs 0.000 description 3
- 150000003840 hydrochlorides Chemical class 0.000 description 3
- 239000012729 immediate-release (IR) formulation Substances 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- 229960000423 loxapine Drugs 0.000 description 3
- 238000007726 management method Methods 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- TTWJBBZEZQICBI-UHFFFAOYSA-N metoclopramide Chemical compound CCN(CC)CCNC(=O)C1=CC(Cl)=C(N)C=C1OC TTWJBBZEZQICBI-UHFFFAOYSA-N 0.000 description 3
- 229940028394 moban Drugs 0.000 description 3
- 208000015122 neurodegenerative disease Diseases 0.000 description 3
- 230000000324 neuroprotective effect Effects 0.000 description 3
- 230000037361 pathway Effects 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 230000036280 sedation Effects 0.000 description 3
- 229940124834 selective serotonin reuptake inhibitor Drugs 0.000 description 3
- 239000012896 selective serotonin reuptake inhibitor Substances 0.000 description 3
- 108010080097 sigma-1 receptor Proteins 0.000 description 3
- 238000007619 statistical method Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 210000003523 substantia nigra Anatomy 0.000 description 3
- 238000013268 sustained release Methods 0.000 description 3
- 239000012730 sustained-release form Substances 0.000 description 3
- 229940095064 tartrate Drugs 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 238000010153 Šidák test Methods 0.000 description 3
- BTFMCMVEUCGQDX-UHFFFAOYSA-N 1-[10-[3-[4-(2-hydroxyethyl)-1-piperidinyl]propyl]-2-phenothiazinyl]ethanone Chemical compound C12=CC(C(=O)C)=CC=C2SC2=CC=CC=C2N1CCCN1CCC(CCO)CC1 BTFMCMVEUCGQDX-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 206010058504 Ballismus Diseases 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
- 206010067671 Disease complication Diseases 0.000 description 2
- 206010061818 Disease progression Diseases 0.000 description 2
- 101710107143 Dopamine receptor 1 Proteins 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- 102000003676 Glucocorticoid Receptors Human genes 0.000 description 2
- 108090000079 Glucocorticoid Receptors Proteins 0.000 description 2
- 102000014150 Interferons Human genes 0.000 description 2
- 108010050904 Interferons Proteins 0.000 description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
- 206010061296 Motor dysfunction Diseases 0.000 description 2
- UQOFGTXDASPNLL-XHNCKOQMSA-N Muscarine Chemical compound C[C@@H]1O[C@H](C[N+](C)(C)C)C[C@H]1O UQOFGTXDASPNLL-XHNCKOQMSA-N 0.000 description 2
- 102000038030 PI3Ks Human genes 0.000 description 2
- 108091007960 PI3Ks Proteins 0.000 description 2
- 108090000430 Phosphatidylinositol 3-kinases Proteins 0.000 description 2
- 108091008611 Protein Kinase B Proteins 0.000 description 2
- 208000001431 Psychomotor Agitation Diseases 0.000 description 2
- 206010038743 Restlessness Diseases 0.000 description 2
- 206010070834 Sensitisation Diseases 0.000 description 2
- 208000005392 Spasm Diseases 0.000 description 2
- 208000000323 Tourette Syndrome Diseases 0.000 description 2
- 208000016620 Tourette disease Diseases 0.000 description 2
- ZZHLYYDVIOPZBE-UHFFFAOYSA-N Trimeprazine Chemical compound C1=CC=C2N(CC(CN(C)C)C)C3=CC=CC=C3SC2=C1 ZZHLYYDVIOPZBE-UHFFFAOYSA-N 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- 208000026935 allergic disease Diseases 0.000 description 2
- WOLHOYHSEKDWQH-UHFFFAOYSA-N amantadine hydrochloride Chemical compound [Cl-].C1C(C2)CC3CC2CC1([NH3+])C3 WOLHOYHSEKDWQH-UHFFFAOYSA-N 0.000 description 2
- 229960002519 amoxapine Drugs 0.000 description 2
- 230000000561 anti-psychotic effect Effects 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- ZPEIMTDSQAKGNT-UHFFFAOYSA-N chlorpromazine Chemical compound C1=C(Cl)C=C2N(CCCN(C)C)C3=CC=CC=C3SC2=C1 ZPEIMTDSQAKGNT-UHFFFAOYSA-N 0.000 description 2
- 229960001076 chlorpromazine Drugs 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 229940088505 compazine Drugs 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000007850 degeneration Effects 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- 230000005750 disease progression Effects 0.000 description 2
- 229940052760 dopamine agonists Drugs 0.000 description 2
- 210000005064 dopaminergic neuron Anatomy 0.000 description 2
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 229960002690 fluphenazine Drugs 0.000 description 2
- 229930195712 glutamate Natural products 0.000 description 2
- 229960003878 haloperidol Drugs 0.000 description 2
- 229960001340 histamine Drugs 0.000 description 2
- 208000013403 hyperactivity Diseases 0.000 description 2
- 230000009610 hypersensitivity Effects 0.000 description 2
- 238000003384 imaging method Methods 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 229940079322 interferon Drugs 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 230000007794 irritation Effects 0.000 description 2
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- SLVMESMUVMCQIY-UHFFFAOYSA-N mesoridazine Chemical compound CN1CCCCC1CCN1C2=CC(S(C)=O)=CC=C2SC2=CC=CC=C21 SLVMESMUVMCQIY-UHFFFAOYSA-N 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 230000009456 molecular mechanism Effects 0.000 description 2
- 230000037023 motor activity Effects 0.000 description 2
- 230000003551 muscarinic effect Effects 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 230000008506 pathogenesis Effects 0.000 description 2
- 230000000737 periodic effect Effects 0.000 description 2
- 229940107333 phenergan Drugs 0.000 description 2
- 229960004265 piperacetazine Drugs 0.000 description 2
- 238000013105 post hoc analysis Methods 0.000 description 2
- 230000001242 postsynaptic effect Effects 0.000 description 2
- 230000003518 presynaptic effect Effects 0.000 description 2
- DSKIOWHQLUWFLG-SPIKMXEPSA-N prochlorperazine maleate Chemical compound [H+].[H+].[H+].[H+].[O-]C(=O)\C=C/C([O-])=O.[O-]C(=O)\C=C/C([O-])=O.C1CN(C)CCN1CCCN1C2=CC(Cl)=CC=C2SC2=CC=CC=C21 DSKIOWHQLUWFLG-SPIKMXEPSA-N 0.000 description 2
- 230000000750 progressive effect Effects 0.000 description 2
- 229960003598 promazine Drugs 0.000 description 2
- 229960003910 promethazine Drugs 0.000 description 2
- 230000000069 prophylactic effect Effects 0.000 description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 238000000159 protein binding assay Methods 0.000 description 2
- 239000002287 radioligand Substances 0.000 description 2
- 238000011552 rat model Methods 0.000 description 2
- 229940080693 reglan Drugs 0.000 description 2
- 238000000611 regression analysis Methods 0.000 description 2
- 230000003252 repetitive effect Effects 0.000 description 2
- 238000009256 replacement therapy Methods 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 230000008313 sensitization Effects 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 230000006641 stabilisation Effects 0.000 description 2
- 238000011105 stabilization Methods 0.000 description 2
- 239000008223 sterile water Substances 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 230000004797 therapeutic response Effects 0.000 description 2
- RVBRTNPNFYFDMZ-SPIKMXEPSA-N thiethylperazine maleate Chemical compound [H+].[H+].[H+].[H+].[O-]C(=O)\C=C/C([O-])=O.[O-]C(=O)\C=C/C([O-])=O.C12=CC(SCC)=CC=C2SC2=CC=CC=C2N1CCCN1CCN(C)CC1 RVBRTNPNFYFDMZ-SPIKMXEPSA-N 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 238000007492 two-way ANOVA Methods 0.000 description 2
- 238000010200 validation analysis Methods 0.000 description 2
- 230000003442 weekly effect Effects 0.000 description 2
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 1
- WSWCOQWTEOXDQX-MQQKCMAXSA-M (E,E)-sorbate Chemical compound C\C=C\C=C\C([O-])=O WSWCOQWTEOXDQX-MQQKCMAXSA-M 0.000 description 1
- BGRJTUBHPOOWDU-NSHDSACASA-N (S)-(-)-sulpiride Chemical compound CCN1CCC[C@H]1CNC(=O)C1=CC(S(N)(=O)=O)=CC=C1OC BGRJTUBHPOOWDU-NSHDSACASA-N 0.000 description 1
- OABRYNHZQBZDMG-INIZCTEOSA-N 5-(3-fluoropropyl)-2,3-dimethoxy-n-[[(2s)-1-prop-2-enylpyrrolidin-2-yl]methyl]benzamide Chemical compound COC1=CC(CCCF)=CC(C(=O)NC[C@H]2N(CCC2)CC=C)=C1OC OABRYNHZQBZDMG-INIZCTEOSA-N 0.000 description 1
- 108091005436 5-HT7 receptors Proteins 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 229940122578 Acetylcholine receptor agonist Drugs 0.000 description 1
- 102000007471 Adenosine A2A receptor Human genes 0.000 description 1
- 108010085277 Adenosine A2A receptor Proteins 0.000 description 1
- 102000006941 Amino Acid Transport System X-AG Human genes 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 208000032116 Autoimmune Experimental Encephalomyelitis Diseases 0.000 description 1
- 102000017926 CHRM2 Human genes 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 101150012960 Chrm2 gene Proteins 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 208000028698 Cognitive impairment Diseases 0.000 description 1
- 241001573498 Compacta Species 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 206010011953 Decreased activity Diseases 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- 102000004073 Dopamine D3 Receptors Human genes 0.000 description 1
- 108090000525 Dopamine D3 Receptors Proteins 0.000 description 1
- 206010013654 Drug abuse Diseases 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 206010015866 Extravasation Diseases 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 108091006151 Glutamate transporters Proteins 0.000 description 1
- 206010061991 Grimacing Diseases 0.000 description 1
- 102000004384 Histamine H3 receptors Human genes 0.000 description 1
- 108090000981 Histamine H3 receptors Proteins 0.000 description 1
- 101000836994 Homo sapiens Sigma non-opioid intracellular receptor 1 Proteins 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 208000008454 Hyperhidrosis Diseases 0.000 description 1
- 102000002227 Interferon Type I Human genes 0.000 description 1
- 108010014726 Interferon Type I Proteins 0.000 description 1
- 102100026720 Interferon beta Human genes 0.000 description 1
- 108010047761 Interferon-alpha Proteins 0.000 description 1
- 102000006992 Interferon-alpha Human genes 0.000 description 1
- 108090000467 Interferon-beta Proteins 0.000 description 1
- 208000015543 Isolated dystonia Diseases 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 108010006519 Molecular Chaperones Proteins 0.000 description 1
- 102000005431 Molecular Chaperones Human genes 0.000 description 1
- 206010028347 Muscle twitching Diseases 0.000 description 1
- 206010052904 Musculoskeletal stiffness Diseases 0.000 description 1
- HOKKHZGPKSLGJE-GSVOUGTGSA-N N-Methyl-D-aspartic acid Chemical compound CN[C@@H](C(O)=O)CC(O)=O HOKKHZGPKSLGJE-GSVOUGTGSA-N 0.000 description 1
- JTVPZMFULRWINT-UHFFFAOYSA-N N-[2-(diethylamino)ethyl]-2-methoxy-5-methylsulfonylbenzamide Chemical compound CCN(CC)CCNC(=O)C1=CC(S(C)(=O)=O)=CC=C1OC JTVPZMFULRWINT-UHFFFAOYSA-N 0.000 description 1
- 206010029260 Neuroblastoma Diseases 0.000 description 1
- 208000036110 Neuroinflammatory disease Diseases 0.000 description 1
- 108010040718 Neurokinin-1 Receptors Proteins 0.000 description 1
- 102000019315 Nicotinic acetylcholine receptors Human genes 0.000 description 1
- 108050006807 Nicotinic acetylcholine receptors Proteins 0.000 description 1
- 101150050331 PGIC gene Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- RGCVKNLCSQQDEP-UHFFFAOYSA-N Perphenazine Chemical compound C1CN(CCO)CCN1CCCN1C2=CC(Cl)=CC=C2SC2=CC=CC=C21 RGCVKNLCSQQDEP-UHFFFAOYSA-N 0.000 description 1
- 102000005765 Proto-Oncogene Proteins c-akt Human genes 0.000 description 1
- 206010071390 Resting tremor Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 102100037346 Substance-P receptor Human genes 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 102000003141 Tachykinin Human genes 0.000 description 1
- 206010044074 Torticollis Diseases 0.000 description 1
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 1
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 1
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 208000028752 abnormal posture Diseases 0.000 description 1
- 229960000276 acetophenazine Drugs 0.000 description 1
- NUKVZKPNSKJGBK-SPIKMXEPSA-N acetophenazine dimaleate Chemical compound [H+].[H+].[H+].[H+].[O-]C(=O)\C=C/C([O-])=O.[O-]C(=O)\C=C/C([O-])=O.C12=CC(C(=O)C)=CC=C2SC2=CC=CC=C2N1CCCN1CCN(CCO)CC1 NUKVZKPNSKJGBK-SPIKMXEPSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000008043 acidic salts Chemical class 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000003044 adaptive effect Effects 0.000 description 1
- 239000003470 adrenal cortex hormone Substances 0.000 description 1
- 229960003790 alimemazine Drugs 0.000 description 1
- 150000001447 alkali salts Chemical class 0.000 description 1
- 208000030961 allergic reaction Diseases 0.000 description 1
- 102000003802 alpha-Synuclein Human genes 0.000 description 1
- 108090000185 alpha-Synuclein Proteins 0.000 description 1
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 1
- 229960001280 amantadine hydrochloride Drugs 0.000 description 1
- 229960003036 amisulpride Drugs 0.000 description 1
- NTJOBXMMWNYJFB-UHFFFAOYSA-N amisulpride Chemical compound CCN1CCCC1CNC(=O)C1=CC(S(=O)(=O)CC)=C(N)C=C1OC NTJOBXMMWNYJFB-UHFFFAOYSA-N 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 229940035678 anti-parkinson drug Drugs 0.000 description 1
- 229940124350 antibacterial drug Drugs 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 239000002249 anxiolytic agent Substances 0.000 description 1
- 229940072107 ascorbate Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 210000001130 astrocyte Anatomy 0.000 description 1
- 239000003693 atypical antipsychotic agent Substances 0.000 description 1
- 229940127236 atypical antipsychotics Drugs 0.000 description 1
- 230000008335 axon cargo transport Effects 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 238000005452 bending Methods 0.000 description 1
- BNQDCRGUHNALGH-UHFFFAOYSA-N benserazide Chemical compound OCC(N)C(=O)NNCC1=CC=C(O)C(O)=C1O BNQDCRGUHNALGH-UHFFFAOYSA-N 0.000 description 1
- 229960000911 benserazide Drugs 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- 229940077388 benzenesulfonate Drugs 0.000 description 1
- 229940050390 benzoate Drugs 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 230000002457 bidirectional effect Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000004397 blinking Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 230000004094 calcium homeostasis Effects 0.000 description 1
- 238000011088 calibration curve Methods 0.000 description 1
- 239000003557 cannabinoid Substances 0.000 description 1
- 229930003827 cannabinoid Natural products 0.000 description 1
- 229940065144 cannabinoids Drugs 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 201000002866 cervical dystonia Diseases 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000013375 chromatographic separation Methods 0.000 description 1
- 229960004170 clozapine Drugs 0.000 description 1
- QZUDBNBUXVUHMW-UHFFFAOYSA-N clozapine Chemical compound C1CN(C)CCN1C1=NC2=CC(Cl)=CC=C2NC2=CC=CC=C12 QZUDBNBUXVUHMW-UHFFFAOYSA-N 0.000 description 1
- 238000011260 co-administration Methods 0.000 description 1
- 208000010877 cognitive disease Diseases 0.000 description 1
- 230000003920 cognitive function Effects 0.000 description 1
- 230000009137 competitive binding Effects 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 229940125782 compound 2 Drugs 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 230000002920 convulsive effect Effects 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- RKHQGWMMUURILY-UHRZLXHJSA-N cortivazol Chemical compound C([C@H]1[C@@H]2C[C@H]([C@]([C@@]2(C)C[C@H](O)[C@@H]1[C@@]1(C)C2)(O)C(=O)COC(C)=O)C)=C(C)C1=CC1=C2C=NN1C1=CC=CC=C1 RKHQGWMMUURILY-UHRZLXHJSA-N 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 230000003412 degenerative effect Effects 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 238000000132 electrospray ionisation Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 229950011470 enantate Drugs 0.000 description 1
- 230000005713 exacerbation Effects 0.000 description 1
- 208000012997 experimental autoimmune encephalomyelitis Diseases 0.000 description 1
- 230000036251 extravasation Effects 0.000 description 1
- 230000004424 eye movement Effects 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 230000008921 facial expression Effects 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 235000021022 fresh fruits Nutrition 0.000 description 1
- 230000008717 functional decline Effects 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 230000000848 glutamatergic effect Effects 0.000 description 1
- IXCSERBJSXMMFS-UHFFFAOYSA-N hcl hcl Chemical compound Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 230000037315 hyperhidrosis Effects 0.000 description 1
- 230000003483 hypokinetic effect Effects 0.000 description 1
- 238000010191 image analysis Methods 0.000 description 1
- 238000012623 in vivo measurement Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000011221 initial treatment Methods 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 230000000155 isotopic effect Effects 0.000 description 1
- 210000004558 lewy body Anatomy 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 238000000622 liquid--liquid extraction Methods 0.000 description 1
- 230000003137 locomotive effect Effects 0.000 description 1
- 238000002595 magnetic resonance imaging Methods 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-M mandelate Chemical compound [O-]C(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-M 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 230000004630 mental health Effects 0.000 description 1
- 230000006996 mental state Effects 0.000 description 1
- 210000001259 mesencephalon Anatomy 0.000 description 1
- 229960000300 mesoridazine Drugs 0.000 description 1
- 230000008986 metabolic interaction Effects 0.000 description 1
- 230000037353 metabolic pathway Effects 0.000 description 1
- 229960004503 metoclopramide Drugs 0.000 description 1
- 238000001690 micro-dialysis Methods 0.000 description 1
- 230000004898 mitochondrial function Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000036651 mood Effects 0.000 description 1
- 230000003387 muscular Effects 0.000 description 1
- OHDXDNUPVVYWOV-UHFFFAOYSA-N n-methyl-1-(2-naphthalen-1-ylsulfanylphenyl)methanamine Chemical compound CNCC1=CC=CC=C1SC1=CC=CC2=CC=CC=C12 OHDXDNUPVVYWOV-UHFFFAOYSA-N 0.000 description 1
- KVBGVZZKJNLNJU-UHFFFAOYSA-N naphthalene-2-sulfonic acid Chemical compound C1=CC=CC2=CC(S(=O)(=O)O)=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-N 0.000 description 1
- 210000001577 neostriatum Anatomy 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 230000003188 neurobehavioral effect Effects 0.000 description 1
- 230000003959 neuroinflammation Effects 0.000 description 1
- 239000003176 neuroleptic agent Substances 0.000 description 1
- 230000000701 neuroleptic effect Effects 0.000 description 1
- 230000009251 neurologic dysfunction Effects 0.000 description 1
- 208000015015 neurological dysfunction Diseases 0.000 description 1
- 201000001119 neuropathy Diseases 0.000 description 1
- 230000007823 neuropathy Effects 0.000 description 1
- 230000004112 neuroprotection Effects 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 150000002823 nitrates Chemical class 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 229960002748 norepinephrine Drugs 0.000 description 1
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- 229960005017 olanzapine Drugs 0.000 description 1
- KVWDHTXUZHCGIO-UHFFFAOYSA-N olanzapine Chemical compound C1CN(C)CCN1C1=NC2=CC=CC=C2NC2=C1C=C(C)S2 KVWDHTXUZHCGIO-UHFFFAOYSA-N 0.000 description 1
- 229940005483 opioid analgesics Drugs 0.000 description 1
- 230000002746 orthostatic effect Effects 0.000 description 1
- GZVBVBMMNFIXGE-CQSZACIVSA-N osu-6162 Chemical compound C1N(CCC)CCC[C@H]1C1=CC=CC(S(C)(=O)=O)=C1 GZVBVBMMNFIXGE-CQSZACIVSA-N 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000001314 paroxysmal effect Effects 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000001991 pathophysiological effect Effects 0.000 description 1
- 230000008289 pathophysiological mechanism Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 230000008447 perception Effects 0.000 description 1
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical class OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 1
- 208000033808 peripheral neuropathy Diseases 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- XNGIFLGASWRNHJ-UHFFFAOYSA-L phthalate(2-) Chemical compound [O-]C(=O)C1=CC=CC=C1C([O-])=O XNGIFLGASWRNHJ-UHFFFAOYSA-L 0.000 description 1
- 230000003334 potential effect Effects 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 1
- 229960004618 prednisone Drugs 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 229960003111 prochlorperazine Drugs 0.000 description 1
- WIKYUJGCLQQFNW-UHFFFAOYSA-N prochlorperazine Chemical compound C1CN(C)CCN1CCCN1C2=CC(Cl)=CC=C2SC2=CC=CC=C21 WIKYUJGCLQQFNW-UHFFFAOYSA-N 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 208000037821 progressive disease Diseases 0.000 description 1
- 230000007111 proteostasis Effects 0.000 description 1
- 229940001470 psychoactive drug Drugs 0.000 description 1
- 239000004089 psychotropic agent Substances 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 238000001303 quality assessment method Methods 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 210000003019 respiratory muscle Anatomy 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 230000001020 rhythmical effect Effects 0.000 description 1
- 229960001534 risperidone Drugs 0.000 description 1
- RAPZEAPATHNIPO-UHFFFAOYSA-N risperidone Chemical compound FC1=CC=C2C(C3CCN(CC3)CCC=3C(=O)N4CCCCC4=NC=3C)=NOC2=C1 RAPZEAPATHNIPO-UHFFFAOYSA-N 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
- 229960001860 salicylate Drugs 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000000862 serotonergic effect Effects 0.000 description 1
- 230000002295 serotoninergic effect Effects 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 229940075554 sorbate Drugs 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 229940114926 stearate Drugs 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 208000011117 substance-related disease Diseases 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 229940086735 succinate Drugs 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 229960004940 sulpiride Drugs 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000008093 supporting effect Effects 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000009747 swallowing Effects 0.000 description 1
- 210000000225 synapse Anatomy 0.000 description 1
- 230000015883 synaptic transmission, dopaminergic Effects 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 108060008037 tachykinin Proteins 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 229960004869 thiethylperazine Drugs 0.000 description 1
- XCTYLCDETUVOIP-UHFFFAOYSA-N thiethylperazine Chemical compound C12=CC(SCC)=CC=C2SC2=CC=CC=C2N1CCCN1CCN(C)CC1 XCTYLCDETUVOIP-UHFFFAOYSA-N 0.000 description 1
- 229960005344 tiapride Drugs 0.000 description 1
- 229960005013 tiotixene Drugs 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 238000011222 transcriptome analysis Methods 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 229960002324 trifluoperazine Drugs 0.000 description 1
- ZEWQUBUPAILYHI-UHFFFAOYSA-N trifluoperazine Chemical compound C1CN(C)CCN1CCCN1C2=CC(C(F)(F)F)=CC=C2SC2=CC=CC=C21 ZEWQUBUPAILYHI-UHFFFAOYSA-N 0.000 description 1
- 229960003904 triflupromazine Drugs 0.000 description 1
- XSCGXQMFQXDFCW-UHFFFAOYSA-N triflupromazine Chemical compound C1=C(C(F)(F)F)C=C2N(CCCN(C)C)C3=CC=CC=C3SC2=C1 XSCGXQMFQXDFCW-UHFFFAOYSA-N 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
- A61K31/198—Alpha-aminoacids, e.g. alanine, edetic acids [EDTA]
Abstract
Description
本出願は、2017年9月8日出願の米国特許仮出願第62/556、314号、及び、2018年3月28日出願の米国特許仮出願第62/649、184号に基づく優先権を主張するものである。上記両出願の開示内容は、参照により本明細書中に援用される。
−同一の医薬製剤の一部である組み合わせとして、2以上の活性化合物が同時に投与される、または
−2以上の単位の組み合わせとして、それぞれが活性物質の1つとともに、同時または同時期に投与される可能性が生じる。
(a)履歴セクション[パート1(オン・ジスキネジア)、及びパート2(オフ・ジストニア)]
(b)客観的セクション[パート3(障害)、及びパート4(能力低下)]
(a)所定量のプリドピジンを含有する医薬組成物と、
(b)薬物誘発性運動障害(DIMD)に罹患した対象を治療するための医薬組成物の使用に関する説明書と、
を備えた、パッケージ。
(a)1以上の単位用量製剤であって、各単位用量製剤が、対象に投与されたときに対象の薬物誘発性運動障害(DIMD)を治療するのに有効な量のプリドピジンを含有する、単位用量製剤と、
(b)1以上の単位用量製剤を収容し、かつ、薬物誘発性運動障害(DIMD)に罹患した患者の治療における当該パッケージの使用を説明するラベルを含む、完成品の医薬容器と、
を備えた、治療用パッケージ。
(a)所定量のプリドピジン、及び薬学的に許容される担体を含有する第1の医薬組成物と、
(b)所定量の第2の化合物、及び薬学的に許容される担体を含有する第2の医薬組成物と、任意選択で、
(c)薬物誘発性運動障害(DIMD)に罹患した対象を治療するための第1の医薬組成物及び第2の医薬組成物の併用使用に関する説明書と、
を備えた、パッケージ。
(a)1以上の単位用量製剤であって、各単位用量製剤が、
(i)所定量のプリドピジン、及び、
(ii)所定量の第2の化合物を含有し、
各単位用量製剤中のプリドピジン及び第2の化合物の各量が、対象に併用投与されたときに対象を治療するのに有効な量である、1以上の単位用量製剤と、
(b)1以上の単位用量製剤を収容し、かつ、患者の治療における当該パッケージの使用を説明するラベルを含む、完成品の医薬容器と、
を備えた、治療用パッケージ。
(a)所定量のプリドピジンと、
(b)所定量の第2の化合物と、を含有し、
当該医薬組成物中の第2の化合物及びプリドピジンの各量が、1以上の単位用量製剤で対象に併用投与したときに対象を治療するのに有効な量である、医薬組成物。
1.この療法は、ジスキネジア症状の改善に有効である。
2、この療法は、鎮静状態、抑うつなどの重大な副作用を伴わない。
3.この療法は、L−DOPAの抗パーキンソン病効果に影響を及ぼさない。
4.この療法は、レボドパにより誘発される「バッドな」オンタイム・クオリティを改善する。
1.この追加療法は、ジスキネジア症状の改善に有効である(少なくとも相加効果またはそれ以上の効果を提供する)。
2.この追加療法は、鎮静状態、抑うつなどの重大な副作用を伴わない。
1.この療法は、DIMDの症状の一部または全部を改善するのに有効である(少なくとも相加効果またはそれ以上の効果を提供する)。
2.この療法は、鎮静状態、抑うつなどの重大な副作用を伴わない。
"Huntexil(登録商標)", The NeurosSearch website, retrieved September 24, 2012, http://neurosearch.com/Default.aspx?ID=8172.
Amantadine PDR 2017 Amantadine hydrochloride - Drug Summary, PDR (Prescribers' Digital Reference), http://www.pdr.net/drug-summary/Amantadine-Hydrochloride-Tablets-amantadine-hydrochloride-2441 and http://www.pdr.net/drug-summary/Amantadine-Hydrochloride-Capsules-amantadine-hydrochloride-1475 accessed September 7, 2017.
Bargiotas P. and Konitsiotis S. 2013. Levodopa-induced dyskinesias in Parkinson's disease: emerging treatments. Neuropsychiatric Disease and Treatment. 9:1605-1617
Brod et al. 2000 Combination therapy with glatiramer acetate (copolymer‐1) and a type I interferon (IFN-α) does not improve experimental autoimmune encephalomyelitis. Annals of Neurology, 47:127-131.
Brust et al. 2014. Molecular Imaging of σ1 Receptors In Vivo: Current Status and Perspectives. Curr. Med. Chem. 21, 35-69.
CSID:25948790, www.chemspider.com/Chemical-Structure.25948790.html (accessed 23:27, Jul 15, 2016).
CSID:7971505, www.chemspider.com/Chemical-Structure.7971505.html (accessed 23:33, Jul 15, 2016).
Cubo et al.2001. Early morning off-medication dyskinesias, dystonia, and choreic subtypes. Arch. Neurol. 58(9):1379-1382.
Daneault, J-F. 2013. Drug-induced dyskinesia in Parkinson's disease. Should success in clinical management be a function of improvement of motor repertoire rather than amplitude of dyskinesia? BMC Medicine, 11:76.
Dizdar, N., et al., 1999. Human pharmacokinetics of L-3,4-dihydroxyphenylalanine studied with microdialysis. Clin Chem 45, 1813-1820.
Ecdeu, GW. 1976. Abnormal Involuntary Movement Scale (AIMS) Assessment Manual for Psychopharmacology: Revised (DHEW publication number ADM 76-338).
Rockville, MD, US Department of Health, Education and Welfare, Public Health Service, Alcohol, Drug Abuse and Mental Health Administration, NIMH Psychopharmacology Research Branch, Division of Extramural Research Programs, 1976: 534-7.
Gerber PE, Lynd LD. 1998. Selective serotonin-reuptake inhibitor-induced movement disorders. Ann Pharmacother 32: 692-698 Geva M, et al., 2016. Pridopidine activates neuroprotective pathways impaired in Huntington Disease. Hum Mol Genet. 25(18):3975-3987.
Goetz et al; 2007. Movement Disorder Society‐sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS‐UPDRS): Process, format, and clinimetric testing plan. Movement Disorders 22(1):41-7.
Goetz et al; 2008a. Movement Disorder Society‐sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS‐UPDRS): Scale Presentation and Clinimetric Testing Results. Movement Disorders 23(15):2129-2170.
Goetz, et al. 2008b. The Unified Dyskinesia Rating Scale: Presentation and Clinimetric Profile. Movement Disorders 23(16):2398-2403.
Goetz, et al, 2013 Which Dyskinesia Scale Best Detects Treatment Response? Movement Disorders 28(3):341-346 Hauser, et al. 2004. Parkinson's disease home diary: Further validation and implications for clinical trials. Movement Dis. 19(12): 1409-1413.
Huot, P, et al, 2012. L-DOPA pharmacokinetics in the MPTP-lesioned macaque model of Parkinson's disease. Neuropharmacology 63, 829-836.
Huot P, et al. 2013 The pharmacology of L-DOPA-induced dyskinesia in Parkinson's disease. Pharmacol Rev 65: 171-222.
Jenner, P. 2008. Molecular mechanisms of L-DOPA-induced dyskinesia. Nature Reviews Neuroscience 9: 665-677.
Johnston, TH et al. and Lee, CS. 2001. "Levodopa-induced dyskinesia: Mechanisms and management " BCMJ 43(4), 206-9.
Johnston, TH, et al, 2013. TC-8831, a nicotinic acetylcholine receptor agonist, reduces L-DOPA-induced dyskinesia in the MPTP macaque. Neuropharmacology 73, 337-347.
Kumar, N., et al,. 2005 Levodopa-dyskinesia incidence by age of Parkinson's disease onset. Mov Disord . 20, 342-344.
Manson, A., et al,. 2012 Levodopa-induced-dyskinesias clinical features, incidence, risk factors, management and impact on quality of life. J Parkinsons Dis 2, 189-198.
Marder K, et al. 2000. Rate of functional decline in Huntington's disease. Neurology 54:452-458.
Movement Disorder Society Task Force on Rating Scales for Parkinson's Disease. 2003. Unified Parkinson's Disease Rating Scale (UPDRS): status and recommendations. Movement Disorders 18(7):738-50.
National Research Council Institute for Laboratory Animal, R., Guide for the Care and Use of Laboratory Animals. National Academies Press (US). Copyright 1996 by the National Academy of Sciences. All rights reserved., Washington (DC).
Poewe, W., Mahlknecht, P., 2009. The clinical progression of Parkinson's disease. Parkinsonism Relat Disord.15 Suppl 4, S28-32.
Ponten H, et al. 2010. In vivo pharmacology of the dopaminergic stabilizer pridopidine. Eur J Pharmacol. 644(1-3):88-95.
Ponten H, et al. 2013. The dopaminergic stabilizer pridopidine decreases expression of L-DOPA-induced locomotor sensitisation in the rat unilateral 6-OHDA model. Eur J Pharmacol. . 698(1-3):278-85.
Sahlholm K, et al. 2013. The dopamine stabilizers ACR16 and (-)-OSU6162 display nanomolar affinities at the σ-1 receptor. Mol Psychiatry. 18:12-14.
Sahlholm K, et al. 2015. Pridopidine selectively occupies sigma-1 rather than dopamine D2 receptors at behaviorally active doses. Psychopharmacol (Berl) 232(18):3443-3453.
Shoulson and Fahn. 1979. Huntington disease: clinical care and evaluation. Neurology 29:1-3.
Slifstein et al. 2010. Striatal and Extrastriatal Dopamine Release Measured With PET and [F-18] Fallypride. Synapse 64(5):350-62.
Tedroff, J, et al. 2004. A pilot study of the novel dopamine stabiliser ACR16 in advanced Parkinson's disease. Movement Disorders, Vol. 19, Suppl. 9, P565.
Thanvi, B. et al. 2007. Levodopa-induced dyskinesia in Parkinson's disease: clinical features, pathogenesis, prevention and treatment. Postgrad Med J; 83:384-388.
米国特許第RE46117号明細書
米国特許第7、923、459号明細書
PCT出願公開第WO2014/205229号
PCT出願公開第WO2017/015609号
PCT出願公開第WO2018/039477号
Claims (36)
- 薬物誘発性運動障害(DIMD)に罹患した対象を治療するための方法であって、
前記対象を治療するのに有効な量のプリドピジンを、前記対象に定期的に投与するステップを含む、方法。 - 前記薬物誘発性運動障害(DIMD)は、ジスキネジアを含む、請求項1に記載の方法。
- 前記ジスキネジアは、レボドパ誘発性ジスキネジア(LID)である、請求項2に記載の方法。
- 前記プリドピジンは、100〜400mg/日、112.5mg/日、125mg/日、135mg/日、150mg/日、175mg/日、180mg/日、200mg/日、225mg/日、250mg/日、300mg/日、350mg/日、または、400mg/日の用量で投与される、請求項3に記載の方法。
- 達成されるAUC0−24が、12、000〜60、000h・ng/ml、20、000〜60、000h・ng/ml、または、25、000〜60、000h・ng/mlである、請求項3または4に記載の方法。
- 前記対象は、パーキンソン病に罹患している、請求項3〜5のいずれかに記載の方法。
- 前記対象は、パーキンソン病以外のパーキンソン症候群に罹患している、請求項3〜5のいずれかに記載の方法。
- 前記対象は、レボドパで同時に治療されている、請求項3〜7のいずれかに記載の方法。
- 前記プリドピジン及び前記レボドパは同時に投与される、請求項8に記載の方法。
- 前記プリドピジン及び前記レボドパは合剤される、請求項9に記載の方法。
- 前記プリドピジン及び前記レボドパは、別個の医薬製剤として連続的に投与される、請求項8に記載の方法。
- 前記プリドピジンの量は、レボドパ治療に関連する症状を緩和または軽減するのに有効な量である、請求項3〜11のいずれかに記載の方法。
- 前記症状は、異常な動き、ミオクローヌス発作、四肢の不規則動作、歩行失調、しかめ面、運動失調、ジストニア様のピークドーズジスキネジア、または、動作、手の動き若しくはバランスの維持困難である、請求項12に記載の方法。
- 前記症状は、レボドパによって誘発されるバッドクオリティ・オンタイムである、請求項12に記載の方法。
- 前記プリドピジンの投与により、MDS−UPDRSまたはUDysRSで測定して、レボドパ誘発性運動障害の症状が、少なくとも10%、少なくとも20%、少なくとも30%、または少なくとも50%改善される、請求項12〜14のいずれかに記載の方法。
- 前記プリドピジンは、経口投与により投与される、請求項1〜15のいずれかに記載の方法。
- 前記プリドピジンは、1日2回または1日3回投与される、請求項1〜16のいずれかに記載の方法。
- 前記プリドピジンは、プリドピジン塩の形態で投与される、請求項1〜17のいずれかに記載の方法。
- 前記プリドピジン塩は、プリドピジン塩酸塩である、請求項18に記載の方法。
- 前記プリドピジンは、プリドピジンHClの形態で、200mg/日の用量で投与される、請求項1〜19のいずれかに記載の方法。
- 前記プリドピジンは、プリドピジンHClの形態で、300mg/日の用量で投与される、請求項1〜19のいずれかに記載の方法。
- 前記プリドピジンは、プリドピジンHClの形態で、350mg/日の用量で投与される、請求項1〜19のいずれかに記載の方法。
- 前記プリドピジンは、プリドピジンHClの形態で、400mg/日の用量で投与される、請求項1〜19のいずれかに記載の方法。
- 前記プリドピジンは、1日2回、等用量で投与される、請求項20〜23のいずれかに記載の方法。
- 達成されるAUC0−24が、25、000〜60、000h・ng/mlである、請求項1〜24のいずれかに記載の方法。
- 前記薬物誘発性運動障害(DIMD)は、抗うつ剤、抗精神病剤、抗てんかん剤、抗菌剤、抗不整脈剤、気分安定剤、胃腸薬、またはそれらの任意の組み合わせから選択される薬物によって誘発される、請求項1に記載の方法。
- 前記薬物誘発性運動障害(DIMD)は、パーキンソン症候群、遅発性ジスキネジア、舞踏病、ジストニア、振戦、静座不能、アテトーシス、ミオクローヌス、またはチックから選択される、請求項1に記載の方法。
- 前記薬物誘発性運動障害(DIMD)は、遅発性ジスキネジアまたは薬物誘発性ジストニアである、請求項27に記載の方法。
- 前記プリドピジンは、45mg/日、90mg/日、100mg/日、112.5mg/日、125mg/日、135mg/日、150mg/日、175mg/日、180mg/日、200mg/日、225mg/日、250mg/日、300mg/日、350mg/日、または、400mg/日の用量で投与される、請求項26〜28のいずれかに記載の方法。
- 前記プリドピジンは、1日2回、等用量で投与される、請求項26〜29のいずれかに記載の方法。
- パッケージであって、
(a)所定量のプリドピジンを含有する医薬組成物と、
(b)薬物誘発性運動障害(DIMD)に罹患した対象を治療するための前記医薬組成物の使用に関する説明書と、
を備えた、パッケージ。 - パッケージであって、
(a)所定量のプリドピジン、及び薬学的に許容される担体を含有する第1の医薬組成物と、
(b)所定量の第2の化合物、及び薬学的に許容される担体を含有する第2の医薬組成物と、任意選択で、
(c)薬物誘発性運動障害(DIMD)に罹患した対象を治療するための前記第1の医薬組成物及び前記第2の医薬組成物の併用使用に関する説明書と、
を備えた、パッケージ。 - 前記薬物誘発性運動障害は、レボドパ誘発性ジスキネジアである、請求項31または32に記載のパッケージ。
- レボドパ誘発性ジスキネジア(LID)を発症するリスクのある対象を治療するための方法であって、
レボドパ誘発性ジスキネジア(LID)の発症を遅延させるか、またはレボドパ誘発性ジスキネジア(LID)を発症するリスクを低下させるのに有効な量のプリドピジンを、前記対象に定期的に投与するステップを含む、方法。 - 前記対象は、パーキンソン病の治療のためのレボドパの投与を受けている、請求項34に記載の方法。
- 前記対象は、パーキンソン病以外のパーキンソン症候群の治療のためのレボドパの投与を受けている、請求項34に記載の方法。
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762556314P | 2017-09-08 | 2017-09-08 | |
US62/556,314 | 2017-09-08 | ||
US201862649184P | 2018-03-28 | 2018-03-28 | |
US62/649,184 | 2018-03-28 | ||
PCT/US2018/048920 WO2019050775A1 (en) | 2017-09-08 | 2018-08-30 | PRIDOPIDINE FOR THE TREATMENT OF DYSKINESIC INDUCED BY A MEDICINAL PRODUCT |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2020533296A true JP2020533296A (ja) | 2020-11-19 |
JP2020533296A5 JP2020533296A5 (ja) | 2021-03-04 |
Family
ID=63684481
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2020513603A Pending JP2020533296A (ja) | 2017-09-08 | 2018-08-30 | 薬物誘発性ジスキネジアを治療するためのプリドピジン |
Country Status (10)
Country | Link |
---|---|
US (2) | US20190231768A1 (ja) |
EP (1) | EP3678664A1 (ja) |
JP (1) | JP2020533296A (ja) |
CN (1) | CN111343982A (ja) |
AU (1) | AU2018329628B2 (ja) |
BR (1) | BR112020004622A2 (ja) |
CA (1) | CA3075020C (ja) |
IL (1) | IL273044A (ja) |
MX (1) | MX2020002645A (ja) |
WO (1) | WO2019050775A1 (ja) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2810092A1 (en) | 2010-09-03 | 2012-03-08 | IVAX International GmbH | Deuterated analogs of pridopidine useful as dopaminergic stabilizers |
US11090297B2 (en) | 2013-06-21 | 2021-08-17 | Prilenia Neurotherapeutics Ltd. | Pridopidine for treating huntington's disease |
MX2019002190A (es) | 2016-08-24 | 2019-09-11 | Prilenia Therapeutics Dev Ltd | Uso de pridopidina para tratar distonías. |
Family Cites Families (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
USRE46117E1 (en) | 1999-12-22 | 2016-08-23 | Teva Pharmaceuticals International Gmbh | Modulators of dopamine neurotransmission |
SE9904724D0 (sv) | 1999-12-22 | 1999-12-22 | Carlsson A Research Ab | New modulators of dopamine neurotransmission I |
WO2006040155A1 (en) | 2004-10-13 | 2006-04-20 | Neurosearch Sweden Ab | Process for the synthesis of 4-(3-methanesulfonylphenyl)-1-n-propyl-piperidine |
SE529246C2 (sv) * | 2005-10-13 | 2007-06-12 | Neurosearch Sweden Ab | Nya disubstituerade fenyl-piperidiner som modulatorer för dopaminneurotransmission |
PT2146961E (pt) | 2007-04-12 | 2014-04-30 | Ivax Int Gmbh | Derivados de n-óxido e/ou di-n-óxido de estabilizadores / moduladores dos recetores da dopamina exibindo perfis de efeitos secundários cardiovasculares melhorados |
EP2170327B1 (en) * | 2007-06-18 | 2014-10-22 | A.Carlsson Research AB | Use of dopamine stabilizers |
US20110206782A1 (en) | 2010-02-24 | 2011-08-25 | Auspex Pharmaceuticals, Inc. | Piperidine modulators of dopamine receptor |
WO2011107583A1 (en) | 2010-03-04 | 2011-09-09 | Nsab, Filial Af Neurosearch Sweden Ab, Sverige | Substituted 4-phenyl-n-alkyl-piperidines for preventing onset or slowing progression of neurodegenerative disorders |
EP2598662A1 (en) | 2010-07-02 | 2013-06-05 | Aktiebolaget SKF | Mechanical component and method for surface hardening |
CA2810092A1 (en) | 2010-09-03 | 2012-03-08 | IVAX International GmbH | Deuterated analogs of pridopidine useful as dopaminergic stabilizers |
EA023462B1 (ru) | 2011-09-07 | 2016-06-30 | Тева Фармасьютикалз Интернэшнл Гмбх | Полиморфная форма гидрохлорида придопидина |
US9012476B2 (en) * | 2011-12-08 | 2015-04-21 | IVAX International GmbH | Hydrobromide salt of pridopidine |
CA2869145A1 (en) | 2012-04-04 | 2013-10-10 | IVAX International GmbH | Pharmaceutical compositions for combination therapy |
KR102316933B1 (ko) | 2013-06-21 | 2021-10-26 | 프리레니아 뉴로테라퓨틱스 엘티디. | 헌팅턴병 치료를 위한 프리도피딘의 용도 |
DK177976B8 (en) | 2013-07-10 | 2021-04-22 | Jasopels As | Apparatus and method for stretching a pelt on a pelt board |
US20150202302A1 (en) | 2014-01-22 | 2015-07-23 | IVAX International GmbH | Modified release formulations of pridopidine |
WO2015138130A1 (en) | 2014-03-10 | 2015-09-17 | Applied Materials, Inc. | Pixel blending for multiple charged-particle beam lithography |
TW201613859A (en) | 2014-06-30 | 2016-04-16 | Teva Pharma | Analogs of PRIDOPIDINE, their preparation and use |
WO2016106142A1 (en) | 2014-12-22 | 2016-06-30 | Teva Pharmaceuticals International Gmbh | L-tartrate salt of pridopidine |
HUE060353T2 (hu) | 2015-02-25 | 2023-02-28 | Prilenia Neurotherapeutics Ltd | Pridopidin alkalmazása memória javítására |
AR105434A1 (es) | 2015-07-22 | 2017-10-04 | Teva Pharmaceuticals Int Gmbh | Proceso para preparar pridopidina |
CA2993183A1 (en) | 2015-07-22 | 2017-01-26 | Teva Pharmaceuticals International Gmbh | Pridopidine base formulations and their use |
US11738012B2 (en) | 2016-02-24 | 2023-08-29 | Prilenia Neurotherapeutics Ltd. | Treatment of neurodegenerative eye disease using pridopidine |
MX2019002190A (es) | 2016-08-24 | 2019-09-11 | Prilenia Therapeutics Dev Ltd | Uso de pridopidina para tratar distonías. |
EP3504187A4 (en) | 2016-08-24 | 2020-05-06 | Prilenia Neurotherapeutics Ltd. | USE OF PRIDOPIDINE FOR THE TREATMENT OF FUNCTIONAL DECLINE |
WO2018053287A1 (en) | 2016-09-15 | 2018-03-22 | Teva Pharmaceuticals International Gmbh | Use of pridopidine for the treatment of anxiety and depression |
WO2018053275A1 (en) | 2016-09-16 | 2018-03-22 | Teva Pharmaceuticals International Gmbh | Use of pridopidine for the treatment of familial dysautonomia |
CN110505902B (zh) | 2017-01-20 | 2022-11-11 | 普瑞尼亚神经治疗有限公司 | 普利多匹定用于治疗脆性x综合征的应用 |
EP3668509B1 (en) | 2017-08-14 | 2022-11-16 | Prilenia Neurotherapeutics Ltd. | Method of treating amyotrophic lateral sclerosis with pridopidine |
CA3073568A1 (en) | 2017-08-30 | 2019-03-07 | Prilenia Neurotherapeutics Ltd. | High concentration dosage forms of pridopidine |
DE102018204527A1 (de) | 2017-09-18 | 2019-03-21 | SEs Solutions GmbH | Dachhalterung für ein Automobil |
-
2018
- 2018-08-30 CN CN201880072818.0A patent/CN111343982A/zh active Pending
- 2018-08-30 AU AU2018329628A patent/AU2018329628B2/en active Active
- 2018-08-30 JP JP2020513603A patent/JP2020533296A/ja active Pending
- 2018-08-30 WO PCT/US2018/048920 patent/WO2019050775A1/en unknown
- 2018-08-30 MX MX2020002645A patent/MX2020002645A/es unknown
- 2018-08-30 EP EP18778648.8A patent/EP3678664A1/en active Pending
- 2018-08-30 BR BR112020004622-1A patent/BR112020004622A2/pt active Search and Examination
- 2018-08-30 CA CA3075020A patent/CA3075020C/en active Active
-
2019
- 2019-04-08 US US16/377,577 patent/US20190231768A1/en not_active Abandoned
- 2019-06-11 US US16/436,947 patent/US11000519B2/en active Active
-
2020
- 2020-03-03 IL IL273044A patent/IL273044A/en unknown
Non-Patent Citations (1)
Title |
---|
EUROPEAN JOURNAL OF PHARMACOLOGY, vol. 698, JPN6021006840, 2013, pages 278 - 285, ISSN: 0004530600 * |
Also Published As
Publication number | Publication date |
---|---|
CA3075020A1 (en) | 2019-03-14 |
BR112020004622A2 (pt) | 2020-09-24 |
AU2018329628B2 (en) | 2021-04-22 |
US20190231768A1 (en) | 2019-08-01 |
IL273044A (en) | 2020-04-30 |
WO2019050775A1 (en) | 2019-03-14 |
EP3678664A1 (en) | 2020-07-15 |
CA3075020C (en) | 2021-12-07 |
MX2020002645A (es) | 2021-06-10 |
AU2018329628A1 (en) | 2020-04-16 |
US11000519B2 (en) | 2021-05-11 |
US20190350914A1 (en) | 2019-11-21 |
CN111343982A (zh) | 2020-06-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8354447B2 (en) | mGLU receptors antagonists for treating disorders associated with mGLU receptors including addiction and depression | |
WO2014052935A2 (en) | Combination of rasagiline and pridopidine for treating neurodegenerative disorders, in particular huntington's disease | |
US11000519B2 (en) | Pridopidine for treating drug induced dyskinesias | |
EP1558231A2 (en) | Dosage escalation and divided daily dose of anti-depressants to treat neurological disorders | |
US11135211B2 (en) | Pimavanserin for treating impulse control disorder | |
CN110505902B (zh) | 普利多匹定用于治疗脆性x综合征的应用 | |
JP2019515891A (ja) | タンニン酸を含有する組成物及びその使用 | |
KR20120101456A (ko) | 중추 매개의 오심 및 구토를 치료하기 위한 조성물 및 방법 | |
US20210060009A1 (en) | Novel methods | |
JP6634445B2 (ja) | ブスピロン代謝産物の使用 | |
WO2011028794A2 (en) | Treatment of huntington's disease with cycloserine and an nmda receptor antagonist | |
US20110034565A1 (en) | Psycho-pharmaceuticals | |
CN113453683A (zh) | 运动障碍的治疗 | |
US20220362241A1 (en) | Novel methods | |
WO2020110128A1 (en) | Combination of pridopidine and an additional therapeutic agent for treating drug induced dyskinesia | |
US20210275512A1 (en) | Pridopidine for treating drug induced dyskinesias | |
EP4329751A1 (en) | Methods of treatment with neuroactive steroids | |
Maan | Comparison of Methamphetamine and MDMA Extended Access Self-administration: Acquisition, Maintenance, and Response Patterns | |
JP2019524682A (ja) | 抗うつ作用の速い発現のためのボルチオキセチン投与計画 | |
Haro et al. | Pharmacological treatment of substance dependence from a neuroscientific perspective (II): alcohol, benzodiazepines and nicotine |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200424 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20200424 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20210125 |
|
A871 | Explanation of circumstances concerning accelerated examination |
Free format text: JAPANESE INTERMEDIATE CODE: A871 Effective date: 20210125 |
|
A975 | Report on accelerated examination |
Free format text: JAPANESE INTERMEDIATE CODE: A971005 Effective date: 20210210 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20210302 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20210622 |
|
C60 | Trial request (containing other claim documents, opposition documents) |
Free format text: JAPANESE INTERMEDIATE CODE: C60 Effective date: 20211020 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20211020 |
|
C22 | Notice of designation (change) of administrative judge |
Free format text: JAPANESE INTERMEDIATE CODE: C22 Effective date: 20221129 |
|
C22 | Notice of designation (change) of administrative judge |
Free format text: JAPANESE INTERMEDIATE CODE: C22 Effective date: 20230110 |
|
C13 | Notice of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: C13 Effective date: 20230207 |
|
C28A | Non-patent document cited |
Free format text: JAPANESE INTERMEDIATE CODE: C2838 Effective date: 20230207 |
|
C22 | Notice of designation (change) of administrative judge |
Free format text: JAPANESE INTERMEDIATE CODE: C22 Effective date: 20230411 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20230501 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230607 |